Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 914 for:    tablet | Japan

A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02401191
Recruitment Status : Completed
First Posted : March 27, 2015
Last Update Posted : November 30, 2015
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objective:

To assess the safety of twice-daily fexofenadine 60 mg/phenylephrine 10 mg (FEX60/PE10) combination tablet in patients with allergic rhinitis.

Secondary Objective:

To evaluate the effectiveness of a twice-daily FEX60/PE10 combination tablet on nasal symptoms (sneezing, rhinorrhea, and nasal congestion), and daily activity impairment.


Condition or disease Intervention/treatment Phase
Rhinitis Allergic Drug: FEX60/PE10 Phase 3

Detailed Description:
It will be 22 days at minimum and up to 32 days depending on screening, treatment, and post-treatment observation allowances.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Non-controlled, Open Study for Assessing the Safety and Effectiveness of a Twice-daily FEX 60 mg - PE 10 mg (FEX60/PE10) Fixed Combination Tablet in Patients With Allergic Rhinitis
Study Start Date : March 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: FEX60/PE10
Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
Drug: FEX60/PE10
Pharmaceutical form:tablet Route of administration: oral




Primary Outcome Measures :
  1. Number of adverse events (Solicited AE reporting) [ Time Frame: From intake of FEX60/PE10 up to approximately 2 weeks ]
  2. Changes from baseline in the nasal congestion score based on the patient's symptom diary [ Time Frame: After 2 weeks treatment ]

Secondary Outcome Measures :
  1. Change from baseline in the total score of 3 nasal symptoms (sneezing, rhinorrhea, and nasal congestion) [ Time Frame: After 2 weeks treatment ]
  2. Change in the total score of 3 nasal symptoms on a daily basis [ Time Frame: After 2 weeks treatment ]
  3. Change in the total score of 3 nasal symptoms during daytime [ Time Frame: After 2 weeks treatment ]
  4. Change in the total score of 3 nasal symptoms during night-time [ Time Frame: After 2 weeks treatment ]
  5. Change in the daily activity impairment score [ Time Frame: After 2 weeks treatment ]
  6. Change in the daily activity impairment score on a daily basis [ Time Frame: After 2 weeks treatment ]
  7. Change in the daily activity impairment score during daytime [ Time Frame: After 2 weeks treatment ]
  8. Change in the daily activity impairment score during night-time [ Time Frame: After 2 weeks treatment ]
  9. Change in nasal findings from baseline: color of inferior turbinate mucosa [ Time Frame: After 2 weeks treatment ]
  10. Change in nasal findings from baseline: congestion of inferior turbinate mucosa [ Time Frame: After 2 weeks treatment ]
  11. Change in nasal findings from baseline: consistency of discharge [ Time Frame: After 2 weeks treatment ]
  12. Assessment of patient's impression after treatment based on patient's symptom diary [ Time Frame: After 2 weeks treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Outpatients with a history of seasonal or perennial allergic rhinitis for at least 1 year confirmed by positive skin prick test to out or indoor allergens (wheal ≥3mm compared to control [diluent]) or positive specific IgE Antibody test (ie, radioallergosorbent test [RAST], etc.) on the day of provisional inclusion in the trial.
  • Patients who meet the following criteria of symptom score. (The symptom score is rated according to the 'Severity of nasal symptoms'):

    1. Nasal congestion score is consistently from 2 to 3 but not 4 for the last 3 days of the screening period.
    2. Score of sneezing or rhinorrhea is consistently 2 or 3 but not 4 throughout the last 3 days of the screening period.
  • Patients aged 15 years or older, with no restriction on gender.
  • Patients written informed consent.
  • Females with childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drug and adequate contraception during the study.

Exclusion criteria:

  • Patients with nasal diseases (hypertrophic rhinitis, paranasal sinusitis, nasal polyps, acute rhinitis, deviation of the nasal septum, etc.) that could interfere with judgment of the efficacy of the investigational product (IP) and patients developing cold-like symptoms during screening period.
  • Patients with severe asthma, bronchiectasis, severe hepatic, renal, or cardiac dysfunction, hematological, endocrine disease, and other serious complications.
  • Patients with unstable medical conditions like diabetes mellitus, heart failure, hepatic and renal impairment.
  • Patients with a history of epilepsy or with organic brain disease, which may cause epilepsy.
  • Patients who have taken any of the following medications that may affect the evaluation of the IP, Patients using intranasal or systemic decongestants if they are not stopped 3 days before the inclusion visit.

    1. Within 1 week prior to the day of registration:

      • Intranasal or oral:

        • Antiallergic drugs, antihistamines, anticholinergic agents, vasoconstrictor, antihistamine-containing cold remedies, agents that can be expected to have an antiallergic/antihistaminic effect (including Chinese medicines and glycyrrhizin), and other agents that are indicated for allergic symptoms (sneezing, rhinorrhea, nasal congestion, etc.).
      • Agents that may affect the blood concentration of Fexofenadine (FEX) (macrolide antibiotics, azole fungicides, and preparations containing aluminum hydroxide/magnesium hydroxide).
    2. Within 2 weeks prior to the day of registration:

      o Steroids, immunosuppressant, and nonspecific alternative therapy (histamine-containing gamma-globulin preparations etc).

    3. Within 4 weeks prior to the day of registration:

      • Patients receiving oral, nasal, inhaled corticosteroids.
      • Depot steroid preparations.
  • Patients using sodium cromoglycate/nedocromil or leukotriene modifiers if they are not stopped 14 days before the inclusion.
  • Patients under immunotherapy if specific immunotherapy has been started or dose changed approximately 1 month preceding enrolment in the study, (doses should maintain the same dose throughout the trial).
  • Patients suffering from Upper Respiratory Tract Infection, sinusitis or acute otitis media within 30 days before the inclusion visit.
  • Patients who are participating in another study or who have previously participated in another study within the previous 6 months prior to the day of registration.
  • Patients who are considered by the Investigator/sub-investigator to be unsuitable for enrolment in the study for any other criterion or previously participated in this study.
  • Patients with a history of hypersensitivity to antihistamines or antiallergic agents including FEX.
  • Patients with severe hypertension or severe coronary artery disease, narrow angle glaucoma, urinary retention, or those who have shown sensitivity to adrenergic agents (manifestations include insomnia dizziness, weakness, tremor, or arrhythmias).
  • Patients receiving monoamine oxidase (MAO) inhibitor therapy or within 2 weeks prior to the day of registration.
  • Women who are pregnant, possibly pregnant, or breast-feeding.
  • Patients with underlying hepatobiliary disease. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02401191


Locations
Layout table for location information
Japan
Sanofi Administrative Office
Tokyo, Japan
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT02401191     History of Changes
Other Study ID Numbers: FEXHYL07477
First Posted: March 27, 2015    Key Record Dates
Last Update Posted: November 30, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases